Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company developing new drug candidates with entirely novel mechanisms. Our research pipeline includes C. diff treatment, antibiotic-resistant Gram-positive infection treatments, Tuberculosis treatments, an ...
Crestone is a team of scientists with experience in the areas of synthetic organic chemistry, process chemistry, analytical chemistry, microbiology, cell biology, biochemistry, and pharmacology. As one of the leading research pharmaceutical companies in Colorado, we take a te ...
We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance. CRS0540 exhibits broad spec ...
CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.
CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.
Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: ...
CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.
Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: ...
Antibiotics are powerful tools in our medical arsenal, but their misuse can lead to dire consequences.
This World Antibiotic Awareness Week, let's pledge to be stewards of our health and global well-being. Responsible antibiotic use is a small step for individuals, a giant l ...
Let's take a moment to express our heartfelt thanks to healthcare providers and clinical researchers for their unwavering dedication to finding solutions for infectious diseases.
Your tireless efforts save lives and inspire us all.
Remember that when facing health issues, your mental well-being matters too.
Reach out, seek support, and prioritize your mental health. You don't have to go through it alone. π
Clostridium difficile infection (CDI) is a gastrointestinal condition caused by toxin-producing strains of C. difficile bacteria. CDI symptoms range from severe diarrhea to toxic megacolon. C. difficile forms spores that are very difficult to eliminate from the hospital envir ...
Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company developing new drug candidates with entirely novel mechanisms. Our research pipeline includes C. diff treatment, antibiotic-resistant Gram-positive infection treatments, Tuberculosis treatments, an ...
At Crestone we are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance.
C. difficile causes severe gut inflammation via toxinβB (TcdB), affecting healthcare settings.
Blocking this process can be a promising treatment approach for CDI.
Antimicrobial resistance is a natural process that can unfortunately make some infections very hard β or even impossible β to treat.
Learn more here: https://t.co/1SwRbnLzq8
Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action, small molecule antimicrobial drugs. Its pipeline includes CRS3123 in clinical development to treat CDI and under investigation t ...
Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action, small molecule antimicrobial drugs. Its pipeline includes CRS3123 in clinical development to treat CDI and under investigation t ...
Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action, small molecule antimicrobial drugs. Its pipeline includes CRS3123 in clinical development to treat CDI and under investigation t ...